

# Product Information & ELISA Manual

Human APRIL/TNFSF13 ELISA Kit (Colorimetric)
NBP3-43451

Enzyme-linked Immunosorbent Assay for quantitative detection.

#### Contact

# **Table of Contents**

| 1. Intended Use                               | 3     |
|---|-------|
| 2. Introduction                               | 3     |
| 3. General References                         | 4     |
| 4. Assay Principle                            | Ę     |
| 5. Handling & Storage                         | Ę     |
| 6. Kit Components                             | Ę     |
| 7. Materials Required but <i>Not</i> Supplied | 6     |
| 8. General ELISA Protocol                     | 7     |
| 8.1. Preparation and Storage of Reagents      | 7     |
| 8.2. Sample collection, storage and dilution  | 8     |
| 8.3. Assay Procedure (Checklist)              | 9     |
| 9. Calculation of Results                     | 10    |
| 10. Typical Data                              | 10    |
| 11. Performance Characteristics               | 11-12 |
| 12. Technical Hints and Limitations           | 13    |
| 13. Troubleshooting                           | 14    |
| 14. Notes                                     | 15    |

## 1. Intended Use

The Human APRIL/TNFSF13 ELISA Kit (Colorimetric) is to be used for the *in vitro* quantitative determination of human APRIL in cell culture supernatants, serum and plasma. This ELISA Kit is for research use only.

## 2. Introduction

The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity (1). APRIL binds to transmembrane activator and CAML interactor (TACI), B cell maturation antigen (BCMA), and heparan sulfate proteoglycans (HSPG) within the extracellular matrix or on the surface of cells such as plasma cells (2). APRIL maintains B cell homeostasis by acting at a later stage, modulating the function and survival of antigen-experienced B cells. APRIL (as well as BAFF) stimulates class-switch recombination (CSR), hence contributes to shaping humoral effector mechanisms. With regards to humoral memory, APRIL is involved in the establishment and survival of the long-lived plasma cell (LLPC) pool in the bone marrow (BM) (3).

APRIL is expressed by a number of myeloid-derived cell types including BM granulocytes, megakaryocytes, eosinophils and osteoclasts and by dendritic cells following exposure to IFN $\alpha$ , IFN $\gamma$  or CD40L. APRIL expression is induced during hematopoiesis in the bone marrow. APRIL expression is not limited to cells of myeloid origin, but can also be found in epithelial cells of the gut, tonsil, breast and skin. Finally, APRIL is expressed in tumor cell lines and human cancer cells of colon, thyroid and lymphoid origin (1).

The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are implicated in several human autoimmune diseases with autoreactive B cell involvement, including systemic lupus erythematosus (SLE) (4), Sjögren's syndrome (SS) (5), IgA nephropathy (IgAN) (6) and rheumatoid arthritis (RA) (7). APRIL might also function in enhancing proliferation of some tumor cells, especially B-cell malignancies (8, 9).

## 3. General References

- (1) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases: E. Samy, et al.; Int. Rev. Immunol. **36**, 3 (2017)
- (2) Identification of proteoglycans as the APRIL-specific binding partners: K. Ingold, et al.; J. Exp. Med. **201**, 1375 (2005)
- (3) Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion: D.C. Nguyen, et al.; Nat. Commun. **12**, 3698 (2018)
- (4) Raised serum APRIL levels in patients with systemic lupus erythematosus: T. Koyama, et al.; Ann. Rheum. Dis. **64,** 1065 (2005)
- (5) The expression of APRIL in Sjogren's syndrome: Aberrant expression of APRIL in the salivary gland: J.L. Vosters, et al.; Rheumatology (Oxford) **51**, 1557 (2012)
- (6) Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy: Y.L. Zhai, et al.; Medicine (Baltimore) **95**, e3099 (2016)
- (7) The BAFF/APRIL system: an important player in systemic rheumatic diseases: F. Mackay, et al.; Curr. Dir. Autoimmun. **8,** 243 (2005)
- (8) APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth: M. Hahne, et al.; J. Exp. Med. **188**, 1185 (1998)
- (9) In situ detection of APRIL-rich niches for plasma-cell survival and their contribution to B-cell lymphoma development: M. Burjanadze, et al.; Histol. Histopathol. **24**, 1061 (2009)

## 4. Assay Principle

This assay is a sandwich Enzyme Linked-Immunosorbent Assay (ELISA) for quantitative determination of human APRIL in cell culture supernatants, serum and plasma (EDTA, heparin or citrate). A monoclonal antibody specific for APRIL has been precoated onto the 96-well microtiter plate. Standards (STD) and samples are pipetted into the wells for binding to the coated antibody. After extensive washing to remove unbound compounds, APRIL is recognized by the addition of a biotinylated monoclonal antibody specific for APRIL (DET). After removal of excess biotinylated antibody, streptavidin-peroxidase (STREP-HRP) is added. Following a washing, peroxidase activity is quantified using the substrate tetramethylbenzidine (TMB). The intensity of the color reaction is measured at 450 nm after acidification and is directly proportional to the concentration of APRIL in the samples.

## 5. Handling & Storage

- Reagent must be stored at 2-8°C when not in use
- Plate and reagents should be at room temperature before use.
- Do not expose reagents to temperatures greater than 25°C.

## 6. Kit Components

2 silica Gel Minibags

| • | 1 plate coated with APRIL Antibody            | (6 x 16-well strips) |                    |
|---|---|----------------------|--------------------|
| • | 2 bottles Wash Buffer 10X                     | (2 x 30 ml)          | (Wash Buffer 10X)  |
| • | 2 bottles ELISA Buffer 10X                    | (2 x 30 ml)          | (ELISA Buffer 10X) |
| • | 1 vial Detection Antibody                     | (20 µl)              | (DET)              |
| • | 1 vial HRP Labeled Streptavidin (lyophilized) | (2 µg)               | (STREP-HRP)        |
| • | 1 vial human APRIL Standard (lyophilized)     | (100 ng)             | (STD)              |
| • | 1 bottle TMB Substrate Solution               | (12 ml)              | (TMB)              |
| • | 1 bottle Stop Solution                        | (12 ml)              | (STOP)             |
| • | 2 plate Covers (plastic film)                 |                      |                    |

# 7. Materials Required but Not Supplied

- Microtiterplate reader at 450nm
- Calibrated precision pipettes. Disposable pipette tips
- Deionized water
- Microtubes or equivalent for preparing dilutions
- Disposable plastic containers for preparing working buffers
- Plate washer: automated or manual
- Glass or plastic tubes for diluting and aliquoting standard

## 8. General ELISA Protocol

# 8.1. Preparation and Storage of Reagents

**NOTE:** Prepare just the appropriate amount of the buffers necessary for the assay.

- Wash Buffer 10X has to be diluted with deionized water 1:10 before use (e.g. 30 ml Wash Buffer 10X + 270 ml water) to obtain Wash Buffer 1X.
- <u>ELISA Buffer 10X</u> has to be diluted with deionized water 1:10 before use (e.g. 10 ml ELISA Buffer 10X + 90 ml water) to obtain ELISA Buffer 1X.
- Detection Antibody (DET) has to be diluted to 1:1000 in ELISA Buffer 1X (10 μl DET + 10 ml ELISA Buffer 1X).

**NOTE:** The diluted Detection Antibody is not stable and cannot be stored!

- HRP Labeled Streptavidin (STREP-HRP) has to be reconstituted with 100 μl of ELISA Buffer 1X.
  - After reconstitution of STREP-HRP, prepare aliquots and store them at -20°C. Avoid freeze/thaw cycles.
  - $_{\odot}$  Dilute the reconstituted STREP-HRP to the working concentration by adding 50  $\mu$ l in 10 ml of ELISA Buffer 1X (1:200).

**NOTE:** The diluted STREP-HRP is not stable and cannot be stored!

- Human APRIL Standard (STD) has to be reconstituted with 100 μl of ELISA Buffer 1X.
  - This reconstitution produces a stock solution of 1 μg/ml. Mix the standard to ensure complete reconstitution and allow the standard to sit for a minimum of 15 minutes at room temperature. Mix well prior to making dilutions.

**NOTE:** The reconstituted standard is aliquoted and stored at -20°C!

- Dilute the standard protein concentrate (STD) (1 μg/ml) in ELISA Buffer 1X. A sevenpoint standard curve using 2-fold serial dilutions in ELISA Buffer 1X is recommended.
- Suggested standard points are:
  250, 125, 62.5., 31.125, 15.5625, 7.78125, 3.90625 and 0 pg/ml.

## Start with the dilution of the concentrate (STD):

| To obtain Add                                 |                           | Into                      |
|---|---------------------------|---------------------------|
| <b>10 ng/ml</b> 10μl of APRIL (STD) (1 μg/ml) |                           | 990 μl of ELISA Buffer 1X |
| 1 ng/ml                                       | 100µl of APRIL (10 ng/ml) | 900 μl of ELISA Buffer 1X |

## Dilute further for the standard curve:

| To obtain    | Add                            | Into                      |  |
|--------------|--------------------------------|---------------------------|--|
| 250 pg/ml    | 300 μl of APRIL (1 ng/ml)      | 900 μl of ELISA Buffer 1X |  |
| 125 pg/ml    | 300 µl of APRIL (250 pg/ml)    | 300 μl of ELISA Buffer 1X |  |
| 62.5 pg/ml   | 300 µl of APRIL (125 pg/ml)    | 300 μl of ELISA Buffer 1X |  |
| 31.25 pg/ml  | 300 μl of APRIL (62.5 pg/ml)   | 300 µl of ELISA Buffer 1X |  |
| 15.625 pg/ml | 300 μl of APRIL (31.25 pg/ml)  | 300 μl of ELISA Buffer 1X |  |
| 7.781 pg/ml  | 300 μl of APRIL (15.625 pg/ml) | 300 μl of ELISA Buffer 1X |  |
| 3.906 pg/ml  | 300 μl of APRIL (7.781 pg/ml)  | 300 μl of ELISA Buffer 1X |  |
| 0 ng/ml      | 300 μl of ELISA Buffer 1X      | Empty tube                |  |

# 8.2. Sample collection, storage and dilution

**Serum**: Use a serum separator tube. Let samples clot at room temperature for 30 minutes before centrifugation for 20 minutes at 1,000xg. Assay freshly prepared serum or store serum in aliquot at ≤ -20°C for later use. Avoid repeated freeze/thaw cycles.

**Plasma**: Collect plasma using heparin, citrate or EDTA as an anticoagulant. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. Assay freshly prepared plasma or store plasma sample in aliquot at  $\leq$  -80°C for later use. Avoid repeated freeze/ thaw cycles.

**Serum, Plasma and Cell Culture Supernatant** have to be diluted in ELISA Buffer 1X. Samples containing visible precipitates must be clarified before use.

**NOTE:** As a starting point, 1/10 dilution of serum or 1/4 dilution of plasma is recommended! If sample values fall outside the detection range of the assay, a lower or higher dilution may be required!

# 8.3. Assay Procedure (Checklist)


| 1.  | Determine the number of 16-well strips needed for the assay and insert them in the frame for current use. The extra strips are left in the bag with 2 silica gel minibags and stored at 4°C.  NOTE: Remaining 16-well strips coated with APRIL antibody when opened can be stored in the presence of 2 silica gel minibags at 4°C for up to 1 month. |
|-----|--|
| 2.  | Add 100 $\mu$ l of the different standards into the appropriate wells in duplicate! At the same time, add 100 $\mu$ l of diluted serum, plasma or cell culture supernatant samples in duplicate to the wells (see 8.1. Preparation and Storage of Reagents and 8.2 Preparation of Samples).  |
| 3.  | Cover the plate with plastic film and incubate for <b>2 hours at Room Temperature</b> .  |
| 4.  | Aspirate the coated wells and add 300 µl of Wash Buffer 1X using a multichannel pipette or auto-washer. Repeat the process for a total of five washes. After the last wash, complete removal of liquid is essential for good performance.  |
| 5.  | Add 100 µl to each well of the diluted Detection Antibody (DET) (see 8.1 Preparation and Storage of Reagents).   |
| 6.  | Cover the plate with plastic film and incubate for 1 hour at room temperature.   |
| 7.  | Aspirate the coated wells and add 300 µl of Wash Buffer 1X using a multichannel pipette or auto-washer. Repeat the process for a total of five washes. After the last wash, complete removal of liquid is essential for good performance.  |
| 8.  | Add 100 µl to each well of the diluted HRP Labeled Streptavidin (STREP-HRP) (see 8.1. Preparation and Storage of Reagents).  |
| 9.  | Cover the plate with plastic film and incubate for <b>30 min at room temperature</b> .   |
| 10. | Aspirate the coated wells and add 300 µl of Wash Buffer 1X using a multichannel pipette or auto-washer. Repeat the process for a total of five washes. After the last wash, complete removal of liquid is essential for good performance.  |
| 11. | Add 100 μl to each well of TMB substrate solution <b>(TMB)</b> .   |
| 12. | Allow the color reaction to develop at room temperature in the dark for 10 minutes. Do not cover the plate.  |
| 13. | Stop the reaction by adding 100 $\mu$ l of Stop Solution ( <b>STOP</b> ). Tap the plate gently to ensure thorough mixing. The substrate reaction yields a blue solution that turns yellow when Stop Solution ( <b>STOP</b> ) is added.   |
|     | ! CAUTION: CORROSIVE SOLUTION!   |
| 14. | Measure the OD at 450 nm in an ELISA reader.   |

## 9. Calculation of Results

- Average the duplicate readings for each standard and sample and subtract the average blank value (obtained with the 0 pg/ml point).
- Generate the standard curve by plotting the average absorbance obtained for each standard concentration on the horizontal (X) axis vs. the corresponding APRIL concentration (pg/ml) on the vertical axis (see **10.** TYPICAL DATA).
- Calculate the APRIL concentrations of samples by interpolation of the regression curve formula as shown above in a form of a quadratic equation
- If the test sample was diluted, multiply the interpolated value by the dilution factor to calculate the concentration of human APRIL in the sample.

## 10. Typical Data

The following data are obtained using the different concentrations of standard as described in this protocol:



| Standard APRIL<br>(pg/ml) | Optical Density<br>(mean) |
|---------------------------|---------------------------|
| 250                       | 2.694                     |
| 125                       | 1.580                     |
| 62.50                     | 0.951                     |
| 31.25                     | 0.549                     |
| 15.63                     | 0.297                     |
| 7.81                      | 0.188                     |
| 3.91                      | 0.118                     |
| 0                         | 0.062                     |

Figure: Standard curve

## 11. Performance Characteristics

## A. Sensitivity (Limit of detection):

The lowest level of human APRIL that can be detected by this assay is 1 pg/ml.

**NOTE**: The Limit of detection was measured by adding three standard deviations to the mean value of 50 zero standard.

**B. Assay range:** 3.90 pg/ml – 250 pg/ml

## C. Specificity:

This ELISA is specific for the measurement of natural and recombinant human APRIL. Detection of APRIL (human) in biological fluids by this ELISA kit is abolished in the presence of a APRIL receptor such as TACI:Fc.




Figure: Specific quantitation of APRIL in human serum.

<u>Method:</u> Serum from a healthy patient is treated with TACI (human):Fc (human) coupled to NHS-Sepharose (or EDAR-Fc beads as control). APRIL levels were measured using the APRIL (human) ELISA Kit.

## D. Intra-assay precision:

Four samples of known concentrations of human APRIL were assayed in replicates 8 times to test precision within an assay.

| Samples    | Means (ng/ml) | SD   | CV (%) | n |
|------------|---------------|------|--------|---|
| <b>A</b> 1 | 2.86          | 0.15 | 5.22   | 8 |
| A2         | 2,60          | 0.15 | 5.70   | 8 |
| A3         | 1.62          | 0.10 | 6.34   | 8 |
| A4         | 0.96          | 0.05 | 5.39   | 8 |

## E. Inter-assay precision:

Four samples of known concentrations of human APRIL were assayed in 5 separate assays to test precision between assays.

| Samples | Means (ng/ml) | SD    | CV (%) | n |
|---------|---------------|-------|--------|---|
| B1      | 2.792         | 0.193 | 6.94   | 5 |
| B2      | 0.155         | 0.015 | 9.37   | 5 |
| В3      | 0.100         | 0.008 | 8.17   | 5 |
| B4      | 0.775         | 0.076 | 9.80   | 5 |

## F. Recovery:

When samples are spiked with known concentrations of human APRIL, the recovery averages range from 92% to 109%.

## G. Linearity:

Different samples containing human APRIL were diluted several fold (1/2 to 1/8 for plasmas and 1/20 to 1/80 for sera) and the measured recoveries ranged from 93% to 109%.

## H. Expected values:

Human APRIL levels range in serum from **0.1 ng/ml to >20 ng/ml** and in plasma from **20 pg/ml to > 1 ng/ml**. Levels of APRIL detected in plasma are lower than in serum.

## 12. Technical Hints and Limitations

- It is recommended that all standards and samples be run in duplicate.
- Do not combine leftover reagents with those reserved for additional wells.
- Reagents from the kit with a volume less than 100µl should be centrifuged.
- Residual wash liquid should be drained from the wells after last wash by tapping the plate on absorbent paper.
- Crystals could appear in the 10X solution due to high salt concentration in the stock solutions.
   Crystals are readily dissolved at room temperature or at 37°C before dilution of the buffer solutions.
- Once reagents have been added to the 16-well strips, DO NOT let the strips DRY at any time during the assay.
- Keep TMB Solution protected from light.
- The Stop Solution (STOP) consists of sulfuric acid. Although diluted, the Stop Solution should be handled with gloves, eye protection and protective clothing.

# 13. Troubleshooting

| PROBLEM                     | POSSIBLE CAUSES                     | SOLUTIONS  |  |
|-----------------------------|-------------------------------------|--|--|
|                             | Omission of key reagent             | Check that all reagents have been added in the correct order.                            |  |
|                             | Washes too stringent                | Use an automated plate washer if possible.   |  |
| No signal or weak<br>signal | Incubation times inadequate         | Incubation times should be followed as indicated in the manual.                          |  |
|                             | Plate reader settings not optimal   | Verify the wavelength and filter setting in the plate reader.                            |  |
|                             | Incorrect assay temperature         | Use recommended incubation temperature. Bring substrates to room temperature before use. |  |
|                             | Concentration of STREP-HRP too high | Use recommended dilution factor.   |  |
| High background             | Inadequate washing                  | Ensure all wells are filling wash buffer and are aspirated completely.                   |  |
| Poor standard curve         | Wells not completely aspirated      | Completely aspirate wells between steps.   |  |
| Poor standard curve         | Reagents poorly mixed               | Be sure that reagents are thoroughly mixed.  |  |
| Unexpected results          | Omission of reagents                | Be sure that reagents were prepared correctly and added in the correct order.            |  |
| ,                           | Dilution error                      | Check pipetting technique and double-check calculations.                                 |  |

# 14. Notes